Financial

News

White House backtracks on medicine price control plans

President Joe Biden has jettisoned a raft of policy proposals aimed at curbing the price of prescription medicines as part of the US administration's $1.75 trillion 'build back better' fram

News

GSK side-lines COVID drug otilimab to focus on Xevudy

GlaxoSmithKline said today it would halt further development of its antibody for severe COVID-19 pneumonia – otilimab – in order to focus its resources on Xevudy for mild-to-moderate diseas

News

Novartis looking into future of its Sandoz' generics busines...

Novartis revealed today that it may consider divesting its generic medicines subsidiary Sandoz – amongst other options – which would further narrow its focus to innovative medicines.

News

Acceleron investors dig their heels in on Merck takeover bid

Activist investors are pushing back against Merck & Co's recent $11.5 billion deal to acquire Acceleron Pharma, arguing that its $180-per-share offer seriously undervalues the company.

News

Biogen's Aduhelm rollout goes from bad to worse

Analysts were predicting sales of Biogen's recently approved Alzheimer's therapy Aduhelm may start to gather a little momentum in the third quarter, but the drug seems to be going into reve

News

J&J mulls switch from non-profit status for COVID jab

Johnson & Johnson has been offering its COVID-19 vaccine for sale on a no-profit basis since it became available, but is thinking about a possible switch to a standard commercial model

White House backtracks on medicine price control plans

GSK side-lines COVID drug otilimab to focus on Xevudy

Novartis looking into future of its Sandoz' generics busines...

Acceleron investors dig their heels in on Merck takeover bid

Biogen's Aduhelm rollout goes from bad to worse

J&J mulls switch from non-profit status for COVID jab

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Financial

Editor's Picks